SCM for Pharma Distribution

The increased complication and sophistication of the pharmaceutical distribution industry has created new and complex challenges. These problems arise due to increasing competitive pressures, shorter product lifecycles, global generic drug distribution, regulatory demands and counterfeit drugs contributing to loss of revenue and brand value.

The Wipro healthcare drug distribution practice comprises of well-trained and highly experienced consultants. Wipro applies Lean and Six Sigma productivity enhancing methodologies to offer customized SCM and integration capabilities to address your problems. This will enable you to implement SCM solutions aligned to your strategic requirements and optimize your IT investments. Our wide range of innovative technology and business solutions include:
  • e-Pedigree framework
  • Radio Frequency Identification (RFID)
  • Regulatory compliance
  • SCM consulting
  • Business Intelligence

e-Pedigree Solution

The Wipro E-Pedigree framework offers a unique "pedigree fragment on demand" model to deliver reliable market-tested platforms. Our solution ensures a reliable and accurate supply chain tracking process, and enhances efficiency and transparency. The Wipro E-Pedigree capabilities offer,
  • Authenticity of origin
  • Clear trail of ownership across the supply chain
  • Reverse supply chain drug tracking
  • Linking of physical inventory movements with B2B transactions
  • Improved returns processing and recall precision

Wipro also provides E-Pedigree consulting services with compliance to state and federal regulations. This helps you align your business strategies with your IT investment to enhance ROI.

 
 
Simplified global systems footprint with streamlined business processes and data
Read how Wipro improved global inventory visibility and product traceability for a diversified healthcare giant by consolidating 31 instances down to 5 core instances.
 
 
 
The state of global clinical research trials
New technologies and changing economic conditions have triggered a number of changes in the pharmaceuticals, life-sciences and biotech sectors. Increasing global sales of life sciences products and growing demand for biologics drugs present drug-industry companies with a host of opportunities.